LDS/Medical Tests/Cytochrome P450 2C8 (CYP2C8) Genotyping

Cytochrome P450 2C8 (CYP2C8) Genotyping

CYP450s are a large family of proteins that oxidize chemicals including therapeutic drugs in the human body. As the main phase I enzymes, they metabolize over 80% of all prescribed drugs in use today. The expression and activity of CYP450 enzymes vary from person to person and is largely affected by genetic variations in the CYP450 genes. Therefore, predictive assessment of genotypes in CYP450 genes is an effective way to help determining drug dosages and prevent adverse side reactions for patients.

CYP2C8 is an important member in the CYP2C protein family. Although CYP2C8 is not among the most abundant CYP450 in the liver, it is highly inducible by statins. The well-known CYP2C8 substrates include the antidiabetics rosiglitazone and pioglitazone, the antiarrhythmic drug amiodarone, the anticancer paclitaxel, the antimalarial amodiaquine, chloroquine and dapsone, and some retinoic acid drugs. The clinical importance of CYP2C8 is revealed by the fatal drug interactions caused by its potent inhibitor gemfibrozil acyl-glucuronide, which ultimately leads to rhabdomyolysis.

The CYP2C8 *2, *3, and *4 variants are commonly seen in Americans, while rare genetic variations with reduced (*8) or no (*5, *7) enzymatic activities are also found in populations. The CYP2C8 *2 allele is mainly seen in 10-22% of African Americans. Both in vivo and in vitro studies have suggested a reduction of enzymatic activities of the three commonly seen variants. It has been shown that the genotypes CYP2C8 *1/*3 or CYP2C8 *3/*3 manifest increased catabolism of CYP2C8 substrates compared with persons who show the CYP2C8 *1/*1 genotype; this includes the drugs repaglinide, rosiglitazone, and pioglitazone. The results suggest the potential importance of drug interactions or differential metabolisms of CYP2C8 targets.

  • Manage the therapeutics of some antimalarials and oral antidiabetics
  • Determining therapeutic strategy for drugs metabolized by CYP2B6
Increased enzyme activity is seen in genotypes with variations \*1/\*3 and \*3/\*3. Decreased enzyme activity is seen in genotypes with variations \*2*, \*3, \*4, \*7, \*8, \*11, \*14 CYP2C8 drug substrates: amodiaquine, Bisphosphonates, cerivastatin, ibuprofen, mycophenolic acid, paclitaxel, pioglitazone, repaglinide, rosiglitazone

CYP2C8 \*1/\*1 (Normal metabolizer)

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), Conventional Sequencing.

Different collection methods are acceptable: buccal swab and peripheral blood (EDTA) or saliva.

Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7 days
Metabolism of therapeutic drugs could be monitored by LC-MS or other methods to better assess ADR or drug dosing. Genotyping of other CYP enzymes may help assess metabolism rates of certain drugs.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login